Ledger.

Startup · $12m raised

Cincera Therapeutics

Coverage

Stories naming Cincera Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

12 deals

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Forbes Australia Thu 3 Sep 2026 AdvanCellAxelia OncologyBrandon CapitalCurrus BiologicsENA RespiratoryLumonusMyricxOncoRes MedicalPolyactivaArnott's GroupCincera TherapeuticsCSIROGates FoundationMain Sequence VenturesNovartisPatties Food GroupProto AxiomTenmileNRF CorporationDr Andrew ForrestBill GatesDr Chris NaveDavid GallMarc BenioffNicola Forrest

Also australiatimes.com

Funding announcement

Biotech incubator CUREator tips $12 million into 19 startups tackling global health

Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.

Startup Daily Fri 2 Jun 2023 AAVec BioAMT BioBioBandageCincera TherapeuticsCoraMetix Pty LtdCytephCytophenixDesmoXDrug discovery platform targeting polynucleotidesExosome BiosciencesFlavivirus vaccine platformFovero TherapeuticsGILZRxKimaritecMicromune TherapeuticsMyrio TherapeuticsProxima BioSycura TherapeuticsxCystence BioANDHealthBrandon BioCatalystCSIROCUREatorMedical Research Future FundMonash UniversityQIMR BerghoferDr Amanda VrseljaDr Chris NaveProfessor Rajiv KhannaDr Sarah Jones
Funding announcement

Nineteen groundbreaking biotech projects selected for national incubator

CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.

Brandon Capital portfolio Wed 24 May 2023 AAVec BioAMT BioBioBandageCincera TherapeuticsCoraMetix Pty LtdCytephCytophenixDesmoXDrug discovery platform targeting polynucleotidesExosome BiosciencesFlavivirus vaccine platformFovero TherapeuticsGILZRxKimaritecMicromune TherapeuticsMyrio TherapeuticsProxima BioSycura TherapeuticsxCystence BioANDHealthBrandon BioCatalystBrandon CapitalCSIROMana CommunicationsMedical Research Future FundMonash UniversityQIMR BerghoferDr Amanda VrseljaDr Chris NaveCiara ByrneJessie WorkmanProfessor Rajiv KhannaDr Sarah Jones
2 deals

Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions

Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.

Brandon BioCatalyst portfolio Thu 3 Sep 2020 Cincera TherapeuticsBioCurateBrandon Capital PartnersBridge and BridgeTech programsCALHNCentre for Cancer BiologyFlinders UniversityMedical Device Partnering ProgramMedical Research Future FundMonash Institute of Pharmaceutical SciencesMonash UniversityMTPConnectQueensland University of TechnologyUniQuestUniSA Ventures Pty LtdUniversity of MelbourneUniversity of QueenslandUniversity of South AustraliaBiomedical Translation BridgeMedical Research Commercialisation Fund (MRCF)Associate Professor Bernard FlynnDr Michael BettessProfessor Stuart Pitson

Also Brandon Capital portfolio·cinceratx.com

Something wrong? Tell us